NO20064642L - Anvendelse av (S,S)- eller racemisk reboxetin - Google Patents

Anvendelse av (S,S)- eller racemisk reboxetin

Info

Publication number
NO20064642L
NO20064642L NO20064642A NO20064642A NO20064642L NO 20064642 L NO20064642 L NO 20064642L NO 20064642 A NO20064642 A NO 20064642A NO 20064642 A NO20064642 A NO 20064642A NO 20064642 L NO20064642 L NO 20064642L
Authority
NO
Norway
Prior art keywords
pain
medicament
manufacture
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
NO20064642A
Other languages
English (en)
Inventor
Bernadette Hughes
Ian Mckenzie
Malcolm John Stoker
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0412878A external-priority patent/GB0412878D0/en
Priority claimed from GB0425061A external-priority patent/GB0425061D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of NO20064642L publication Critical patent/NO20064642L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Det beskrives anvendelse av (S,S)- eller racemisk reboxetin eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament for behandling av en smertetilstand valgt blant neuropatisk smerte, nociceptiv smerte, cancersmerte, ryggsmerte, inflammatorisk smerte, muskelskjelettsmerte, visceral smerte, smerte fra spenning/vrikking, postoperativ smerte, posttraumatisk smerte, brannskader, renal kolikk, akutt smerte, sentralnervesystemtraume, hodesmerte og orofacial smerte. Anvendelse av (S,S)- reboxetin eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament for behandling av smerte i en pasient refraktær til en alfa-2-delta ligand og anvendelse av (S,S)- eller racemisk reboxetin eller et farmasøytisk akseptabelt salt derav for fremstilling av et medikament for anvendelse for mental prestasjon eller som sinnsstemningsforbedrer beskrives også.
NO20064642A 2004-06-09 2006-10-12 Anvendelse av (S,S)- eller racemisk reboxetin NO20064642L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0412878A GB0412878D0 (en) 2004-06-09 2004-06-09 Use
US58865204P 2004-07-16 2004-07-16
GB0425061A GB0425061D0 (en) 2004-11-12 2004-11-12 Use
US63442704P 2004-12-07 2004-12-07
PCT/IB2005/001904 WO2006000903A2 (en) 2004-06-09 2005-05-27 Use of reboxetine for the treatment of pain

Publications (1)

Publication Number Publication Date
NO20064642L true NO20064642L (no) 2006-11-13

Family

ID=34979099

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064642A NO20064642L (no) 2004-06-09 2006-10-12 Anvendelse av (S,S)- eller racemisk reboxetin

Country Status (12)

Country Link
US (1) US20080261984A1 (no)
EP (1) EP1763354A2 (no)
JP (1) JP2008501778A (no)
KR (1) KR20070029740A (no)
AU (1) AU2005256944A1 (no)
BR (1) BRPI0511941A (no)
CA (1) CA2567365A1 (no)
IL (1) IL178827A0 (no)
MX (1) MXPA06014389A (no)
NO (1) NO20064642L (no)
RU (1) RU2006143659A (no)
WO (1) WO2006000903A2 (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090233959A1 (en) 2008-02-19 2009-09-17 Adolor Corporation Beloxepin and analogs for the treatment of pain
US20130310385A1 (en) * 2012-05-18 2013-11-21 Gruenenthal Gmbh Pharmaceutical Composition Comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine and Antidepressants
US9345689B2 (en) 2012-05-18 2016-05-24 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N, N-dimethyl-4-phenyl-4,9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and an anticonvulsant
US9320725B2 (en) 2012-05-18 2016-04-26 Gruenenthal Gmbh Pharmaceutical composition comprising (1r,4r)-6′-fluoro-N,N-dimethyl-4-phenyl-4′9′-dihydro-3′H-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and a gabapentinoid
CA3098205A1 (en) * 2018-04-17 2019-10-24 Shanghai Tonglian Pharmaceutical Co., Ltd. Medicament for preventing and/or treating pain and/or fever, composite product and use thereof
WO2019222850A1 (en) * 2018-05-23 2019-11-28 Wex Pharmaceuticals Inc. Synergistic tetrodotoxin formulations and methods of treatment for neuropathic pain
WO2019245975A1 (en) * 2018-06-17 2019-12-26 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US20190381056A1 (en) * 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
CN112888430A (zh) * 2018-10-15 2021-06-01 艾克萨姆治疗公司 瑞波西汀治疗发作性睡病的用途
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
WO2021113163A1 (en) * 2019-12-03 2021-06-10 Axsome Therapeutics, Inc. Use of reboxetine to treat nervous system disorders
US12565478B1 (en) 2025-01-21 2026-03-03 Axsome Therapeutics, Inc. (S)-2-((S)-(2-ethoxyphenoxy)(phenyl)methyl)-4-nitrosomorpholine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US422449A (en) * 1890-03-04 Gage for gas-cocks
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
DE60022692T2 (de) * 1999-07-01 2006-06-22 Pharmacia & Upjohn Co. Llc, Kalamazoo (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
EP1632235A3 (en) * 1999-07-01 2006-06-14 Pharmacia & Upjohn Company LLC Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
BRPI0413726A (pt) * 2003-09-09 2006-11-07 Pfizer Prod Inc combinação de inibidores da recaptação de serotonina e inibidores da recaptação de norepinefrina
AU2004271800A1 (en) * 2003-09-12 2005-03-24 Pfizer Inc. Combinations comprising alpha-2-delta ligands and serotonin / noradrenaline re-uptake inhibitors

Also Published As

Publication number Publication date
WO2006000903A3 (en) 2006-06-08
WO2006000903A2 (en) 2006-01-05
BRPI0511941A (pt) 2008-01-22
KR20070029740A (ko) 2007-03-14
IL178827A0 (en) 2007-03-08
RU2006143659A (ru) 2008-06-20
US20080261984A1 (en) 2008-10-23
EP1763354A2 (en) 2007-03-21
MXPA06014389A (es) 2007-02-19
AU2005256944A1 (en) 2006-01-05
JP2008501778A (ja) 2008-01-24
CA2567365A1 (en) 2006-01-05

Similar Documents

Publication Publication Date Title
RU2013111077A (ru) Дипептидное пролекарство, его применение и лекарственное средство
NO20064642L (no) Anvendelse av (S,S)- eller racemisk reboxetin
JO2282B1 (en) Oxazole derivatives
EA200970287A1 (ru) Способы, соединения, композиции и носители, подходящие для доставки 3-амино-1-пропансульфоновой кислоты
EA201070046A1 (ru) Способ получения лекарственного средства, содержащего тадалафил
UA98961C2 (uk) Похідні піразинону та їх застосування у лікуванні легеневих захворювань
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
CY1112067T1 (el) Χρηση φλιμπανσερινης για την θεραπεια διαταραχων προ-εμμηνοπαυσιακης σεξουαλικης επιθυμιας
CY1116057T1 (el) Παραγωγα κιναζολιν-4(3η)-ονης που χρησιμοποιουνται ως αναστολεις κινασης ρι3
IS2696B (is) Setin 2-amínótetralín fyrir meðhöndlunina á geðdeyfð
GEP20084452B (en) Sulfonamide derivatives for the treatment of diseases
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
EA201270205A1 (ru) Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
EA200801580A1 (ru) Новые производные пирониндола и способ их получения
TN2009000275A1 (en) Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome
RU2015105821A (ru) Способ адъювантного лечения рака
TW200621765A (en) Substituted phenylaminothiazoles and their use
NZ593199A (en) Milnacipran for the long-term treatment of fybromyalgia syndrome
ATE507827T1 (de) Behandlung pervasiver entwicklungsstörungen
DK2244703T3 (da) Lægemiddel og fremstillingen og anvendelse deraf i behandlingen af smertefulde neuropatier
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them
JP2008501778A5 (no)
RU2008127882A (ru) Лечение пищевода барретта
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application